Engineered flavivirus vaccines control induction of crossreactive infection-enhancing and -neutralizing antibodies
Issued Date
2022-10-06
Resource Type
ISSN
0264410X
eISSN
18732518
Scopus ID
2-s2.0-85137927482
Pubmed ID
36109279
Journal Title
Vaccine
Volume
40
Issue
42
Start Page
6004
End Page
6011
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccine Vol.40 No.42 (2022) , 6004-6011
Suggested Citation
Yamanaka A., Rattanaamnuaychai P., Matsuda M., Suzuki R., Matsuura Y., Tatsumi M., Konishi E. Engineered flavivirus vaccines control induction of crossreactive infection-enhancing and -neutralizing antibodies. Vaccine Vol.40 No.42 (2022) , 6004-6011. 6011. doi:10.1016/j.vaccine.2022.09.012 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/83582
Title
Engineered flavivirus vaccines control induction of crossreactive infection-enhancing and -neutralizing antibodies
Other Contributor(s)
Abstract
Flaviviruses are important human pathogens because of their global distribution and disease severity. The high structural similarity among flaviviruses induces cross-immunity, with individual flaviviruses exhibiting crossreactive infection-enhancing and/or -neutralizing activities against other flaviviruses. Unlike neutralizing antibodies, enhancing antibodies may increase the risk of disease severity. Vaccine-induced enhancement remains a concern in the development of flavivirus vaccines. Here, we immunized mice with DNA vaccine candidates (pcJEME, pcWNME or pcZIKME) against Japanese encephalitis virus (JEV), West Nile virus (WNV) or Zika virus (ZIKV), respectively, and investigated crossreactive neutralizing and enhancing antibody activities against seven flaviviruses. pcZIKME induced higher cross-neutralization against dengue viruses than against JEV and WNV. Moreover, pcZIKME with a single amino acid substitution (D87N) showed an increase in crossreactive neutralizing activity and a decrease in enhancing activities against other flaviviruses. A similar trend was observed in pcWNME. Engineered antigen might contribute to the development of safe and effective flavivirus vaccines.